⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ALLR News
Allarity Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
ALLR
Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign
globenewswire.com
ALLR
Form 8-K
sec.gov
ALLR
Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office
globenewswire.com
ALLR
Form 8-K
sec.gov
ALLR
Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer
globenewswire.com
ALLR
Form 8-K
sec.gov
ALLR
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress
globenewswire.com
ALLR
Form 8-K
sec.gov
ALLR
Form 8-K
sec.gov
ALLR